Pitfalls bei der Ga-68-PSMA-PET/CT

Zusammenfassung

Die PSMA-PET/CT ist ein innovatives nuklearmedizinisches Untersuchungsverfahren, das in letzter Zeit zunehmenden Einzug in die klinische Versorgung von Patienten mit Prostatakarzinomen hält. Für die adäquate Befundung der Bilddaten besteht aufgrund bisher erst geringer Fallzahlen aktuell nur eine begrenzte klinische Erfahrung. Das physiologische Verteilungsmuster des Tracers, sowie typische pathologische Anreicherungsmechanismen zu kennen, ist für die korrekte Beurteilung unerlässlich. Diese Arbeit beschreibt das Anreicherungsmuster des Tracers sowie mögliche typische Fallstricke, die bei der sachgerechten Befundung der PSMA-PET/CT beachtet werden sollten.

Abstract

PSMA-PET/CT is an innovative imaging tool for diagnostics and staging of prostate cancer which is increasingly used in clinical routine. Due to a comparable low amount of patients examined up to now, there is only a limited clinical experience with this new method which is on the other side essential for an adequate judgment of the PET/CT data. This article gives an overview of the physiological biodistribution of the tracer as well as typical pitfalls. This knowledge is crucial for the correct interpretation of PSMA-PET/CT.

Schlüsselwörter

PET/CT - PSMA - Verteilungsmuster - Pitfalls

Key words

PET/CT - PSMA - tracer distribution - pitfalls

• Literatur

• 1 AWMF-Register-Nummer 043/022OL: Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, 2014
• 2 Afshar-Oromieh A, Haberkorn U, Schlemmer HP et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 2014; 41: 887-897
• 3 Afshar-Oromieh A, Malcher A, Eder M et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40: 486-495
• 4 Afshar-Oromieh A, Avtzi E, Giesel FL et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209
• 5 Bostwick DG, Pacelli A, Blute M et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82: 2256-2261
• 6 Chang SS, Reuter VE, Heston WD et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59: 3192-3198
• 7 Demirci E, Ocak M, Kabasakal L et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 2014; 41: 1461-1462
• 8 Eder M, Eisenhut M, Babich J et al. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 2013; 40: 819-823
• 9 Eder M, Wangler B, Knackmuss S et al. Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies. Eur J Nucl Med Mol Imaging 2008; 35: 1878-1886
• 10 Eiber M, Maurer T, Souvatzoglou M et al. Evaluation of Hybrid (6)(8)Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015; 56: 668-674
• 11 Hillier SM, Kern AM, Maresca KP et al. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med 2011; 52: 1087-1093
• 12 Kratochwil C, Giesel FL, Eder M et al. [(1)(7)(7)Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 987-988
• 13 Krohn T, Verburg FA, Pufe T et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging 2015; 42: 210-214
• 14 Mannweiler S, Amersdorfer P, Trajanoski S et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009; 15: 167-172
• 15 Morigi JJ, Stricker P, Van Leeuwen P et al. Prospective Comparison of the detection rate of18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy. J Nucl Med 2015; Jun 25
• 16 Nomura N, Pastorino S, Jiang P et al. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int 2014; 14: 26
• 17 Rajasekaran SA, Anilkumar G, Oshima E et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 2003; 14: 4835-4845
• 18 Silver DA, Pellicer I, Fair WR et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 81-85
• 19 Sweat SD, Pacelli A, Murphy GP et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52: 637-640
• 20 Verburg FA, Krohn T, Heinzel A et al. First evidence of PSMA expression in differentiated thyroid cancer using [Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging 2015; Apr 28